- English (USA)
- English (UK)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Verrica Pharmaceuticals Inc (VRCA)
Verrica Pharmaceuticals Inc stock price live, this page displays NASDAQ VRCA stock exchange data. View the VRCA premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Verrica Pharmaceuticals Inc real time stock price chart below.
What Is the Verrica Pharmaceuticals Inc Stock Price Today?
The Verrica Pharmaceuticals Inc stock price today is 0.81.
What Is the Stock Symbol for Verrica Pharmaceuticals Inc?
The stock symbol for Verrica Pharmaceuticals Inc is "VRCA."
What Stock Exchange Does Verrica Pharmaceuticals Inc Trade On?
Verrica Pharmaceuticals Inc is listed and trades on the NASDAQ stock exchange.
Is Verrica Pharmaceuticals Inc a Good Stock to Buy?
Determining whether Verrica Pharmaceuticals Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the VRCA quote. (ISIN: US92511W1080)
What Is the Verrica Pharmaceuticals Inc Stock Price Today?
The Verrica Pharmaceuticals Inc stock price today is 0.81.
What Is the Stock Symbol for Verrica Pharmaceuticals Inc?
The stock symbol for Verrica Pharmaceuticals Inc is "VRCA."
What Stock Exchange Does Verrica Pharmaceuticals Inc Trade On?
Verrica Pharmaceuticals Inc is listed and trades on the NASDAQ stock exchange.
Is Verrica Pharmaceuticals Inc a Good Stock to Buy?
Determining whether Verrica Pharmaceuticals Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the VRCA quote. (ISIN: US92511W1080)
Currency in USD
0.81
-0.07(-8.02%)
Closed·
After Hours
0.79-0.02(-2.47%)
·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
0.77
0.90
52 wk Range
0.38
8.98
VRCA Scorecard
Full Analysis
Analysts anticipate sales growth in the current year
VRCA is not included in our AI-picked strategies. See which stocks are.
Review Strategies
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
0.770.90
52 wk Range
0.388.98
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
VRCA Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Price Target
4.00
Upside
+393.83%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Quickly burning through cash
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Sell
Moving Averages
Buy
Verrica Pharmaceuticals Company Profile
Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and sale of medications for the treatment of skin diseases in the United States. The company’s product pipeline includes YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for treating external genital warts, as well as for molluscum contagiosum. It also develops VP-315, an oncolytic peptide-based injectable therapy that is in phase II clinical trial for the treatment of dermatology oncologic conditions, which include basal cell carcinoma; and VP-103, a cantharidin-based product candidate for treating plantar warts. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for dermatological oncology indications, such as non-metastatic melanoma and non-metastatic merkel cell carcinoma. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.
Verrica Pharmaceuticals Inc SWOT Analysis
YCANTH's Rocky Road | Explore Verrica's struggles with YCANTH's launch, facing negative revenues and market penetration challenges despite strategic efforts to improve distribution |
Leadership Shake-Up | Delve into Verrica's management overhaul and strategic review, aimed at salvaging YCANTH's position and restoring financial stability amid operational hurdles |
VP-315: A New Hope | Learn about Verrica's promising VP-315 for basal cell carcinoma, showing a 51% clearance rate in phase II trials, potentially diversifying the company's portfolio |
Financial Crossroads | Analysts set price targets ranging from $2 to $14, reflecting uncertainty in Verrica's turnaround efforts and the critical nature of YCANTH's performance |
Verrica Pharmaceuticals Inc Earnings Call Summary for Q1/2025
- Q1 2025 revenue reached $3.4M, driven by WICANT's 16.7% sequential growth in dispensed units, exceeding 10,000 quarterly for the first time
- GAAP net loss of $9.7M ($0.10/share); Non-GAAP net loss of $7.8M ($0.08/share); Cash and equivalents at $29.6M as of March 31, 2025
- Stock rose 8.63% in regular trading but fell 7.09% after hours; currently trades at $0.51, down 95% over the past year
- Company focuses on WICANT commercialization and expanding to independent pharmacies; advancing BP315 for basal cell carcinoma
- Analysts project 107% revenue growth this fiscal year; price targets range $2-$5; average recommendation 2.33
Last Updated: 14-05-2025, 02:50 am
Read Full TranscriptCompare VRCA to Peers and Sector
Metrics to compare | VRCA | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipVRCAPeersSector | |
|---|---|---|---|---|
P/E Ratio | −1.1x | −3.7x | −0.5x | |
PEG Ratio | −0.03 | 0.00 | 0.00 | |
Price/Book | −4.0x | 1.0x | 2.6x | |
Price / LTM Sales | 10.4x | 2.2x | 3.1x | |
Upside (Analyst Target) | 393.8% | 93.2% | 46.1% | |
Fair Value Upside | Unlock | 12.3% | 6.9% | Unlock |
Analyst Ratings
2 Buy
2 Hold
0 Sell
Ratings:
4 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 4.00
(+393.83% Upside)
Earnings
Latest Release
May 13, 2025
EPS / Forecast
-0.08 / -0.11
Revenue / Forecast
3.44M / 2.48M
FAQ
What Is the Verrica Pharmaceuticals (VRCA) Stock Price Today?
The Verrica Pharmaceuticals stock price today is 0.81.
What Stock Exchange Does Verrica Pharmaceuticals Trade On?
Verrica Pharmaceuticals is listed and trades on the Nasdaq Stock Exchange stock exchange.
What Is the Stock Symbol for Verrica Pharmaceuticals?
The stock symbol for Verrica Pharmaceuticals is "VRCA."
What Is the Verrica Pharmaceuticals Market Cap?
As of today, Verrica Pharmaceuticals market cap is 74.60M.
What Is Verrica Pharmaceuticals's Earnings Per Share (TTM)?
The Verrica Pharmaceuticals EPS (TTM) is -1.03.
When Is the Next Verrica Pharmaceuticals Earnings Date?
Verrica Pharmaceuticals will release its next earnings report on 11 Aug 2025.
From a Technical Analysis Perspective, Is VRCA a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has Verrica Pharmaceuticals Stock Split?
Verrica Pharmaceuticals has split 0 times.
How Many Employees Does Verrica Pharmaceuticals Have?
Verrica Pharmaceuticals has 71 employees.
What is the current trading status of Verrica Pharmaceuticals (VRCA)?
As of 12 Jul 2025, Verrica Pharmaceuticals (VRCA) is trading at a price of 0.81, with a previous close of 0.87. The stock has fluctuated within a day range of 0.77 to 0.90, while its 52-week range spans from 0.38 to 8.98.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.